Brief: U.S. FDA Approves First Topical Gene Therapy For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa

Krystal Biotech

19/05/2023 18:51

May 19 (Reuters) - U.S. FDA: 
    * U.S.FDA - APPROVES FIRST TOPICAL GENE THERAPY FOR
TREATMENT OF
WOUNDS IN PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA
    * U.S. FDA- APPROVAL OF VYJUVEK WAS GRANTED TO KRYSTAL
BIOTECH,
INC

Further company coverage:  KRYS.O 

 ((Reuters.Briefs@thomsonreuters.com;))